AstraZeneca PLC has received its second warning in four months from the U.S. Food and Drug Administration (news - web sites) over what the agency says are misleading claims in its ads for cholesterol-lowering medicine Crestor. The latest letter, which was received in the last few days, said claims that Crestor lowers cholesterol better than Pfizer Inc.'s market leading medicine Lipitor (news - web sites) are misleading because it cherry picks results from a study comparing the two medicines. The information was reported on Forbes.com Friday.
